Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice

Lung Cancer

Volumn 29, Issue 3, 2000, Pages 205-216

  Mattson, K ^a   Bosquee, L ^b   Dabouis, G ^c   Le Groumellec, A ^d   Pujol, J L ^e   Marien, S ^f   Stupp, R ^g   Douillard, J Y ^h   Bragas B ⁱ   Berille, J ⁱ   Olivares, R ⁱ   Le Chevalier, T ^j  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Centre Hospitalier Regional de La Citadelle   (Belgium)

^c HÔTEL DIEU   (France)

^d Centre Hospitalier P Chubert   (France)

^e HÔPITAL ARNAUD DE VILLENEUVE   (France)

^f Dienst Pneumologie ^*  (Belgium)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h CENTRE RENÉ GAUDUCHEAU   (France)

ⁱ SANOFI   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Community setting; Docetaxel; First line; Second line

Indexed keywords

CORTICOSTEROID; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAIL DISEASE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0034283120     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00122-7     Document Type: Article

References (20)

1. Bonomi P., Kim K., Chang A., et al. Phase III trial comparing etoposide-cisplatin versus taxol with cisplatin granulocyte colony stimulating factor versus taxol cisplatin in advanced non small cell lung cancer: an Eastern Cooperative Oncology Group trial. Proc. Am. Soc. Clin. Oncol. 15:1996;1145. Abstr.
2. Bunn P.A., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non small cell lung cancer - a review of the literature and future directions. Clin. Cancer Res. 5:1998;1087-1100.
3. Crino L., Mosconi A.M., Scagliotti G., et al. Salvage treatment with gemcitabine (GEM) in pretreated as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J. Clin Oncol 1999;17:2081-2085 (NSCLC). Proc. Am. Soc. Clin. Oncol. 16:1997;446a. Abstr.
4. Fossella F.V. Single-agent docetaxel in patients with refractory non small cell lung cancer. Oncology. 11:(Suppl. 7):1997;11-15.
5. 2 vs vinorelbine/ifosfamide for non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy (PBC). Proc. Am. Soc. Clin. Oncol. 18:1999;460a. Abstr.
6. Fumoleau P., Chevallier B., Kerbrat P., et al. First line chemotherapy with Taxotere in advanced breast cancer: a phase II study of the EORTC Clinical Screening group. Proc. Am. Soc. Clin. Oncol. 12:1993;27. Abstr.
7. Gandara DR, Vokes E, Green M et al. Activity of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer: results of a phase II multicenter trial (in press).
8. Giaconne G., Splinter T.A.W., Debruyne C., et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 16:1998;2133-2141.
9. Le Chevalier T., Brigsand D., Douillard J.Y., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non small cell lung cancer: results of a European multicentre trial including 612 patients. J. Clin. Oncol. 12:1994;360-367.
10. Miller AB, FRCP/C: Hoogstraten B, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
11. Nauman C., Delaney T.F., Park J., et al. Paclitaxel (Taxol®) as a single agent salvage therapy in non-small cell lung cancer (NSCLC). Proc. Am. Clin. Oncol. 16:1997;476a. Abstr.
12. Non Small Cell Lung Cancer Cooperative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
13. Rigas J. Single-agent docetaxel in previously untreated non small cell lung cancer. Oncology. 11:(Suppl. 7):1997;17-21.
14. Roszkowski K. Taxotere® (TXT) versus best supportive care (BSC) in chemosensitive patients with unresectable non-small cell lung cancer (NSCLC): final results of the phase III study. Eur. J. Cancer. 35:(Suppl. 4):1999;S246. Abstr. 976.
15. Schrijvers D., Wanders J., Dirix L., et al. Coping with toxicities of docetaxel. Ann. Oncol. 4:1993;610-611.
16. Shepherd F., Gralla R., Ramlau R., et al. Randomised study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. Eur. J. Cancer. 35:(Suppl. 4):1999;S247. Abstr 979.
17. Summary of Product Characteristics of Taxotere12 formulation 3, european labelling.
18. Valero V., Waters R., Theriault R., et al. Phase II study of docetaxel (Taxotere) in anthracycline refractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 13:1994;470. Abstr 1636.
19. Westeel V., Jacoulet P., Dubiez A., et al. Second line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC). ECCO. 9:1997;1063. Abstr.
20. Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group Study. J. Clin. Oncol. 16:(7):1998;2459-2465.